Document:

Exhibit
4.6

 

THIS
WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE
ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT OR APPLICABLE EXEMPTION OR SAFE HARBOR PROVISION.

 

COMMON
STOCK PURCHASE WARRANT

 

ADHERA
THERAPEUTICS INC.

 

	Warrant
    Shares: 800,000	Initial
    Issue Date: June 25, 2021
	Aggregate
    Exercise Amount: $76,000	 

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, GS CAPITAL PARTNERS, LLC, or its
assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date hereof (the “Initial Issue Date”) and on or prior to the close of business
on the three (3) year anniversary of the Initial Issue Date (as subject to adjustment hereunder, the “Termination Date”),
to subscribe for and purchase from ADHERA THERAPEUTICS INC., a California corporation (the “Company”), up to 800,000
shares (as subject to adjustment herein, the “Warrant Shares”) of common stock of the Company (the “Common
Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 1.2.

 

ARTICLE
1 EXERCISE RIGHTS

 

The
Holder will have the right to exercise this Warrant to purchase shares of Common Stock as set forth below.

 

1.1
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time,
by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered
Holder at the address of the Holder appearing on the books of the Company) of a duly executed facsimile or emailed copy of the Notice
of Exercise form annexed hereto. Within three (3) business days following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or check drawn on a United
States bank unless the cashless exercise procedure specified in Section 1.3 below is specified in the applicable Notice of Exercise.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the
date of such purchases. The Company shall deliver any objection to any Notice of Exercise form within two (2) business days of receipt
of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of
this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.

 

1.2
Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $0.095 per share, subject to adjustment
hereunder (the “Exercise Price”). The aggregate exercise price is $76,000.

 

1.3
Cashless Exercise. In the event that shares covered by this Warrant are not subject to a registration statement at the time
of exercise, then, in addition to a cash exercise, this Warrant may also be exercised, in whole or in part, at such time by means
of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient
obtained by dividing [(A-B) (X)] by (A), where:

 

    	1

    	 

    

 

	 	(A)
    	=	the
    closing price of the Common Stock immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless
    exercise,” as set forth in the applicable Notice of Exercise;
	 	 	 	 
	 	(B)	=	the
    Exercise Price of this Warrant, as adjusted hereunder; and 
	 	 	 	 
	 	(X)
    	=	the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
    exercise were by means of a cash exercise rather than a cashless exercise.

 

1.4
Delivery of Warrant Shares. Warrant Shares purchased hereunder will be delivered to Holder within three (3) business days of Notice
of Exercise by “DWAC/FAST” electronic transfer (such date, the “Warrant Share Delivery Date”) or by delivery
of physical certificate. The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named
therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date of delivery of the Notice of
Exercise. Holder may assess penalties or liquidated damages (both referred to herein as “penalties”) as follows. For each
exercise, in the event that shares are not delivered by the third business day (inclusive of the day of exercise if received before 4:00
pm EST), the Company shall pay the Holder in cash a penalty of $1,000 per day for each day after the third business day until share delivery
is made. The Company will not be subject to any penalties once its transfer agent correctly processes the shares to the DWAC system.
The Company will make its best efforts to deliver the Warrant Shares to the Holder the same day or next day.

 

1.5
Delivery of Warrant. The Holder shall not be required to physically surrender this Warrant to the Company. If the Holder has purchased
all of the Warrant Shares available hereunder and the Warrant has been exercised in full, this Warrant shall automatically be cancelled
without the need to surrender the Warrant to the Company for cancellation. If this Warrant shall have been exercised in part, the Company
shall, at the request of Holder and upon surrender of this Warrant, at the time of delivery of the Warrant Shares, deliver to the Holder
a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant
shall in all other respects be identical with this Warrant and, for purposes of Rule 144, shall tack back to the original date of this
Warrant.

 

1.6
Intentionally Omitted.

 

1.7
Compensation for Buy-In on Failure to Timely Deliver Certificates Upon Exercise. In addition to any other rights available to
the Holder, if the Company fails to abide by the terms of this Warrant and fails to cause its transfer agent to transmit to the Holder
the Warrant Shares on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including
brokerage commissions and other fees, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times
(2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either
(x) reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case
such exercise shall be deemed rescinded), (y) deliver to the Holder the number of shares of Common Stock that would have been issued
had the Company timely complied with its exercise and delivery obligations hereunder, or (z) pay in cash to the Holder the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed. The Holder shall provide the
Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence
of the amount of such loss.

 

    	2

    	 

    

 

1.8
Make-Whole for Market Loss after Exercise. At the Holder’s election, if the Company fails to abide by the terms of this
Warrant and fails to deliver to the Holder the Warrant Shares by DWAC/FAST electronic transfer (such as by delivering a physical certificate)
and if the Holder incurs a Market Price Loss, then at any time subsequent to incurring the loss the Holder may provide the Company written
notice indicating the amounts payable to the Holder in respect of the Market Price Loss and the Company must make the Holder whole as
follows:

 

Market
Price Loss = [(High trade price on the day of exercise) x (Number of Warrant Shares)] – [(Sales price realized by Holder) x (Number
of Warrant Shares)]

 

The
Company must pay the Market Price Loss by cash payment, and any such cash payment must be made by the third business day from the time
of the Holder’s written notice to the Company.

 

1.9
Make-Whole for Failure to Deliver Loss. At the Holder’s election, if the Company fails to abide by the terms of this Warrant
and fails for any reason to deliver to the Holder the Warrant Shares by the Warrant Share Delivery Date and if the Holder incurs a Failure
to Deliver Loss, then at any time the Holder may provide the Company written notice indicating the amounts payable to the Holder in respect
of the Failure to Deliver Loss and the Company must make the Holder whole as follows:

 

Failure
to Deliver Loss = [(High trade price at any time on or after the day of exercise) x (Number of Warrant Shares)]

 

The
Company must pay the Failure to Deliver Loss by cash payment, and any such cash payment must be made by the third business day from the
time of the Holder’s written notice to the Company.

 

1.10
Choice of Remedies. Nothing herein, including, but not limited to, Holder’s electing to pursue its rights under Sections
1.8 or 1.9 of this Warrant, shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure
to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

1.11
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Company for any issue or transfer
tax or other incidental expense in respect of the issuance of such shares, all of which taxes and expenses shall be paid by the Holder,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder. The Holder
shall pay all transfer agent fees required for same-day processing of any Notice of Exercise.

 

1.12
Holder’s Exercise Limitations. Unless otherwise agreed in writing by both the Company and the Holder, at no time will the
Holder exercise any amount of this Warrant to purchase Common Stock that would result in the Holder owning more than 9.9% of the Common
Stock outstanding of the Company (the “Beneficial Ownership Limitation”). Upon the written request of Holder, the
Company shall within two (2) business days confirm in writing to the Holder the number of shares of Common Stock then outstanding.

 

ARTICLE
2 ADJUSTMENTS

 

2.1
Stock Dividends and Splits. If the Company, at any other time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 2.1 shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.

 

    	3

    	 

    

 

2.2
Pro Rata Distributions. If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common
Stock (and not to the Holder) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe
for or purchase any security other than the Common Stock, then in each such case the Exercise Price shall be adjusted by multiplying
the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution
by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned above, and of which the numerator
shall be such VWAP on such record date less the then per share fair market value at such record date of the portion of such assets or
evidence of indebtedness or rights or warrants so distributed applicable to one outstanding share of the Common Stock as determined by
the Board of Directors in good faith. In either case the adjustments shall be described in a statement provided to the Holder of the
portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such
adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned
above.

 

2.3
Intentionally Omitted.

 

2.3
Notice to Holder. Whenever the Exercise Price is adjusted pursuant to any provision of this Article 2, the Company and the Holder
shall promptly notify each other (by written notice) setting forth the proposed Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ARTICLE
3 COMPANY COVENANTS

 

3.1
Reservation of Shares. As of the issuance date of this Warrant and for the remaining period during which the Warrant is exercisable,
the Company will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of Warrant
Shares upon the full exercise of this Warrant. The Company represents that upon issuance, such Warrant Shares will be duly and validly
issued, fully paid and non-assessable. The Company agrees that its issuance of this Warrant constitutes full authority to its officers,
agents and transfer agents who are charged with the duty of executing and issuing shares to execute and issue the necessary Warrant Shares
upon the exercise of this Warrant. No further approval or authority of the stockholders of the Board of Directors of the Company is required
for the issuance of the Warrant Shares

 

3.2
No Adverse Actions. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including,
without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of
the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without
limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body
having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

ARTICLE
4 MISCELLANEOUS

 

4.1
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.

 

4.2
Transferability. Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder (including,
without limitation, any registration rights) are transferable, in whole or in part, by a written assignment of this Warrant duly executed
by the Holder or its agent or attorney. If necessary to obtain a new warrant for any assignee, the Company, upon surrender of this Warrant,
shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of
this Warrant not so assigned, and such new Warrants, for purposes of Rule 144, shall tack back to the original date of this Warrant.
The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without
having a new Warrant issued.

 

    	4

    	 

    

 

4.3
Assignability. The Company may not assign this Warrant. This Warrant will be binding upon the Company and its successors, and
will inure to the benefit of the Holder and its successors and assigns, and may be assigned by the Holder to anyone of its choosing without
the Company’s approval.

 

4.4
Notices. Any notice required or permitted hereunder must be in writing and either personally served, sent by facsimile or email
transmission, or sent by overnight courier. Notices will be deemed effectively delivered at the time of transmission if by facsimile
or email, and if by overnight courier the business day after such notice is deposited with the courier service for delivery.

 

4.5
Governing Law. This Warrant will be governed by, and construed and enforced in accordance with, the laws of the State of New York,
without regard to the conflict of laws principles thereof. Any action brought by either party against the other concerning the transactions
contemplated by this Warrant shall be brought only in the state courts of New York or in the federal courts located in the State of New
York. Both parties and the individuals signing this Agreement agree to submit to the jurisdiction of such courts.

 

4.6
Delivery of Process by Holder to the Company. In the event of any action or proceeding by Holder against the Company, and only
by Holder against the Company, service of copies of summons and/or complaint and/or any other process which may be served in any such
action or proceeding may be made by Holder via U.S. Mail, overnight delivery service such as FedEx or UPS, or process server to the Company
at its last known address or to its last known attorney set forth in its most recent SEC filing.

 

4.7
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 1.1. So long as this Warrant is unexercised, this
Warrant carries no voting rights and does not convey to the Holder any “control” over the Company, as such term may be interpreted
by the SEC under the Securities Act or the Exchange Act, regardless of whether the price of the Company’s Common Stock exceeds
the Exercise Price.

 

4.8
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.

 

4.9
Attorney Fees. In the event any attorney is employed by either party to this Warrant with regard to any legal or equitable action,
arbitration or other proceeding brought by such party for the enforcement of this Warrant or because of an alleged dispute, breach, default
or misrepresentation in connection with any of the provisions of this Warrant, the prevailing party in such proceeding will be entitled
to recover from the other party reasonable attorneys’ fees and other costs and expenses incurred, in addition to any other relief
to which the prevailing party may be entitled.

 

4.10
Opinion of Counsel. In the event that an opinion of counsel is needed for any matter related to this Warrant, Holder has the right
to have any such opinion provided by its counsel.

 

4.11
Nonwaiver. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies.

 

4.12
Amendment Provision. The term “Warrant” and all references thereto, as used throughout this instrument, means this
instrument as originally executed, or if later amended or supplemented, then as so amended or supplemented.

 

4.13
No Shorting. Holder agrees that so long as this Warrant remains unexercised in whole or in part, Holder will not enter into or
effect any “short sale” of the common stock or hedging transaction which establishes a net short position with respect to
the common stock of the Company. The Company acknowledges and agrees that as of the date of delivery to the Company of a fully and accurately
completed Notice of Exercise, Holder immediately owns the common shares described in the Notice of Exercise and any sale of those shares
issuable under such Notice of Exercise would not be considered short sales.

 

*
* *

 

    	5

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.

 

	 	ADHERA THERAPEUTICS INC.
	 	 	 
	 	By:
    	                               
	 	 	 
	 	HOLDER: GS CAPITAL PARTNERS, LLC
	 	 	 
	 	By:	 

 

    	6

    	 

    

 

NOTICE
OF EXERCISE

 

To:
ADHERA THERAPEUTICS INC.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

[  ] in lawful money of the United States; or

 

[  ] the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in Section 1.3, to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
Section 1.3.

 

(3)
Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is
specified below:

 

_______________________________

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4)
Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

 

Name:
_______________________________________

Date:
________________________________________EX-10.1

 Exhibit 10.1 

ASSET PURCHASE AGREEMENT 

This ASSET PURCHASE AGREEMENT (the “Agreement”) is entered into as of August 17, 2021 (the “Effective
Date”), by and between Aerpio Pharmaceuticals, Inc., a Delaware corporation on behalf of itself and its wholly-owned subsidiaries (“Seller”), and EyePoint Pharmaceuticals, Inc., a Delaware corporation
(“Purchaser”). 
 RECITALS 

WHEREAS, Seller desires to sell, assign, transfer, convey and deliver to Purchaser, and Purchaser desires to purchase, acquire and
accept from Seller, the Transfer Assets (as defined below), upon the terms and subject to the conditions hereinafter set forth. 

AGREEMENT 
 NOW
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Purchaser and Seller hereby agree as follows: 

1. Sale of Transfer Assets. Upon the terms and subject to the conditions of this Agreement, in consideration of and in exchange for the
consideration set forth in Sections 3, Seller agrees, on the Closing Date (as defined below), to sell, transfer, assign and convey to Purchaser, and Purchaser hereby agrees to purchase, acquire and accept from Seller, all of Seller’s right,
title and interest in and to the Transfer Assets (as defined below) “as is”, “where is”, and without recourse (except as expressly set forth in this Agreement), and (except as set forth in Section 8 below) without
representations or warranties of any kind, express or implied, including, without limitation, any warranties as to quiet enjoyment, merchantability, value, useful life, fitness for intended use, or similar representations and warranties. On the
Closing Date, Seller and Purchaser shall execute and deliver to each other a Bill of Sale, substantially in the form attached hereto as Exhibit A, and a Patent Assignment, substantially in the form attached hereto as
Exhibit D. For purposes of this Agreement, “Transfer Assets” shall mean the following: 
 (a) the
patents and patent applications listed on Exhibit B attached hereto (the “Patents”). 
 2.
Excluded Assets. Notwithstanding anything to the contrary in this Agreement, the Transfer Assets shall not include any of the Excluded Assets and the Excluded Assets shall not be transferred to Purchaser, but shall be retained by Seller. For
purposes of this Agreement, “Excluded Assets” shall include all assets of Seller not expressly listed as “Transfer Assets”, including without limitation the following items: 

(a) all cash, cash equivalents and uncashed checks held or received by Seller prior to the Closing Date; 

 (b) any right that Seller has with respect to tax refunds, claims for tax refunds and tax
attributes arising prior to the Closing Date; 
 (c) except as otherwise expressly set forth herein, all books and records of the Seller;

 (d) the rights or obligations granted to the Seller under this Agreement; 

(e) any rights or claims under any insurance policies of the Seller; and 

(f) any claims or causes of action arising from or relating to the Seller’s use, ownership or operation of the Transfer Assets prior to
the Closing, other than claims for infringement or misappropriation of the Patents and other intellectual property rights included in the Transfer Assets. 

3. Consideration. As consideration for the sale, transfer, assignment and conveyance to Purchaser of the Transfer Assets on the Closing
Date, Purchaser shall, within one business day following the Effective Date, pay Seller a one-time, non-refundable (except as provided in
Section 14(n)), non-creditable payment of Four Hundred Fifty Thousand Dollars ($450,000) (the “Purchase Amount”). Upon Seller’s receipt of the Purchase Amount,
the Purchase Amount shall be held in escrow pursuant to the terms of the Joint Escrow Instructions attached to this Agreement as Exhibit E. On the Effective Date, Purchaser and Seller shall execute and deliver to the individual designated as
the escrow agent in the Joint Escrow Instructions or person’s designee (the “Escrow Agent”) the Joint Escrow Instructions, which will be held and used by the Escrow Agent pursuant to the terms of the Joint Escrow Instructions.
For the avoidance of doubt, the Joint Escrow Instructions provide that the Purchaser and Seller shall instruct the Escrow Agent to release the Purchase Amount to Seller following the satisfaction or waiver of the conditions precedent set forth in
Sections 6 and 7. 
 4. Obligations Assumed. 

(a) Liabilities. Purchaser agrees, upon consummation of, and effective as of, the Closing, to assume all liabilities, obligations and
commitments of Seller of any nature whatsoever under or related the Transfer Assets, other than liabilities arising out of or relating to conduct accruing prior to the Closing Date (collectively, the “Assumed Liabilities”). 

(b) Liabilities and Obligations Not Assumed. Except for the Assumed Liabilities, Purchaser shall not assume or become obligated in any
way to pay any liabilities, debts or obligations of Seller whatsoever, including but not limited to any liabilities or obligations now or hereafter arising from Seller’s business activities that took place prior to the Closing or any
liabilities arising out of or connected to any action or inaction of Seller in connection with the liquidation and winding down of Seller’s business. All liabilities, debts and obligations of Seller not expressly assumed by Purchaser hereunder
as Assumed Liabilities are hereinafter referred to as the “Excluded Liabilities.” 

  
 2 

 (c) No Obligations to Third Parties. The execution and delivery of this Agreement
shall not be deemed to confer any rights upon any person or entity other than the parties hereto, or make any person or entity a third party beneficiary of this Agreement, or to obligate either party to any person or entity other than the parties to
this Agreement. Assumption by Purchaser of any liabilities or obligations of Seller under Section 4(a) shall in no way expand the rights or remedies of third parties against Purchaser as compared to the rights and remedies such parties would
have against Seller if the Closing were not consummated. 
 5. Closing. The closing of the purchase and sale of the Transfer Assets
(the “Closing”) shall occur promptly following the satisfaction or waiver of the conditions precedent set forth in Sections 6 and 7 below at such time and place as Seller and Purchaser mutually agree, orally or in writing, and may
be effected by the email or facsimile exchange of closing deliverables hereunder (or in such other manner, as the parties shall mutually agree in writing). The date on which the Closing is consummated is referred to herein as the “Closing
Date.” Assets meeting the definition of Transfer Assets delivered to Purchaser by or on behalf of Seller either on or after the Closing Date shall be deemed to be Transfer Assets for all purposes of this Agreement. 

(a) With respect to the materials listed on Exhibit C attached hereto (the “Materials”), each of Seller and Purchaser
shall use commercially reasonable efforts (A) to endeavor to obtain the consents, approvals, clearances, ratifications, permissions, authorizations or waivers from any third parties that control the Materials to cause Purchaser to take title or
assume (as applicable) the Materials as of and subject to the Closing (provided that neither Seller nor Purchaser shall be required to expend money, commence, defend or participate in any litigation or offer or grant any accommodation (financial or
otherwise) to any such third party), and (B) to cooperate, upon written request of Purchaser, in endeavoring to obtain for Purchaser, at no cost to Seller, an arrangement to provide to the Purchaser, in compliance with law, substantially
comparable interests in the Materials as held by Seller immediately prior to the closing. For avoidance of doubt, Seller shall be deemed to have satisfied its obligations under the preceding sentence if, on or before the Closing Date: 

i. With respect to the Materials under the heading “Singota Materials,” Seller shall have delivered a Letter of Assignment, in the
form previously delivered to Purchaser and signed by the Seller, to the possessor of such Materials. 
 ii. With respect to the Materials
under the heading “Aroz Technologies Materials,” Seller shall have delivered a Letter of Assignment, in the form previously delivered to Purchaser and signed by the Seller, to the possessor of such Materials. 

iii. With respect to the Materials under the heading “Charles River Materials,” Seller shall have delivered a Letter of Assignment,
in the form previously delivered to Purchaser and signed by the Seller, to the possessor of such Materials. 
 iv. With respect to the
Materials under the heading “Intrinsik IND Materials,” Seller shall have delivered letters to the FDAs in substantially the form attached hereto as Exhibit F-1 and Exhibit F-2, duly executed by Seller, providing notification of the transfer to the Purchaser of all rights of the Seller in and to such Materials. 

v. With respect to the Materials under the heading “Intrinsik Other Materials,” Seller shall have delivered a Letter of Assignment,
in the form previously delivered to Purchaser and signed by the Seller, to the possessor of such Materials. 

  
 3 

 vi. With respect to the Materials under the heading “SDC Materials,” Seller shall
have delivered a Letter of Assignment, in the form previously delivered to Purchaser and signed by the Seller, to the possessor of such Materials. 

vii. With respect to the Materials under the heading “MedPace Materials,” Seller shall have delivered a Letter of Assignment, in the
form previously delivered to Purchaser and signed by the Seller, to the possessor of such Materials. 
 viii. With respect to the Materials
under the heading “Experis Materials,” Seller shall have delivered a Letter of Assignment, in the form previously delivered to Purchaser and signed by the Seller, to the possessor of such Materials. 

ix. With respect to the Materials under the heading “Iron Mountain Materials,” Seller shall have delivered a Letter of Assignment,
in the form previously delivered to Purchaser and signed by the Seller, or such other documentation as may be appropriate to convey the Iron Mountain Materials to Purchaser at Closing, to the possessor of such Materials. 

x. With respect to the Materials under the heading “Electronic Records,” Seller shall have made such Materials available for
download by Purchaser. 
 (b) Following the Effective Date and prior to the Closing, Seller will make available to Purchaser some or all of
the Materials and such Materials shall be deemed to be Confidential Information under that certain Bilateral Confidentiality and Non-Disclosure Agreement, dated March 23, 2021, between Seller and
Purchaser. In the event that this Agreement is terminated prior to Closing, promptly following such termination, Purchaser shall destroy or return to Seller, at Seller’s sole discretion, any Materials delivered or made available to Purchaser in
accordance with Seller’s instructions. 
 6. Seller’s Conditions Precedent. Seller’s obligations to
consummate the Closing shall be conditioned upon the satisfaction or waiver of the following: 
 (a) The representations and warranties of
Purchaser contained in Section 9 shall be true on and as of Closing. 
 (b) The Purchaser shall have performed or complied with all
agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by the Purchaser on or before the Closing. 

(c) The Seller shall have consummated a merger with Aspen Merger Subsidiary, Inc., a Delaware corporation (the “Merger”). 

(d) The Purchaser shall have executed and delivered to the Escrow Agent the Joint Escrow Instructions in the form attached as
Exhibit E hereto. 
 (e) As of the Closing Date, the sale of the Transfer Assets by Seller or any of the
transactions contemplated hereby are not prohibited by any stay or injunction in any litigation, governmental action, or other proceeding, including, without limitation, the “automatic stay” under 11 U.S.C. § 362 in any pending case
under Title 11 of the United States Code by or against Seller. 

  
 4 

 7. Purchaser’s Conditions Precedent. Purchaser’s obligations
to consummate the Closing shall be conditioned upon the satisfaction or waiver of the following: 
 (a) The representations and warranties of
Seller contained in Section 8 shall be true on and as of Closing. 
 (b) The Seller shall have performed or complied with all
agreements, obligations and conditions contained in this Agreement and required to be performed or complied with by it on or before the Closing, including, but not limited to, Seller’s obligations pursuant to
Section 5(a). 
 (c) As of the Closing Date, the sale of the Transfer Assets by Seller or any of the transactions
contemplated hereby are not prohibited by any stay or injunction in any litigation, governmental action, or other proceeding, including, without limitation, the “automatic stay” under 11 U.S.C. § 362 in any pending case under Title 11
of the United States Code by or against Seller. 
 (d) The Seller shall have executed and delivered to the Escrow Agent the Joint Escrow
Instructions in the form attached as Exhibit E hereto. 
 (e) The Seller shall have executed and delivered to
Purchaser a Bill of Sale in the form attached as Exhibit A hereto and a Patent Assignment in the form attached hereto as Exhibit D, with respect to the Transfer Assets. 

8. Representations and Warranties of Seller. Except as to Seller’s representations and warranties expressly provided below, the
Transfer Assets are being sold “as is,” and “where is” with no express or implied representations or warranties of any kind, nature, or type whatsoever from or on behalf of, Seller. For purposes of this Agreement, the
“Knowledge of Seller” means the actual knowledge of Seller, without any duty of inquiry. 
 (a) Seller (i) is a
corporation duly organized, validly existing, and in good standing under the laws of its jurisdiction of incorporation and (ii) has all requisite corporate power and authority to execute and deliver this Agreement and to perform the
transactions contemplated hereby. 
 (b) The execution, delivery, and performance by Seller of this Agreement and the consummation of the
transaction contemplated hereby are within the power of Seller and have been duly authorized by all necessary actions on the part of Seller. The execution of this Agreement by Seller constitutes, or will at the Closing constitute, a legal, valid and
binding obligation of Seller, enforceable against Seller in accordance with its terms, except as limited by bankruptcy, insolvency, or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and
general principles of equity. 
 (c) No consent, approval, authorization or order of, or registration or filing (other than any filing to be
made with the U.S. Patent Office to record the Patent Assignment) with, or notice to, any court or governmental agency or body having jurisdiction or regulatory authority over Seller (or any of its properties) is required for (i) Seller’s
execution and delivery of this Agreement (and each agreement executed and delivered by it in connection herewith) or (ii) the consummation by Seller of the transactions contemplated by this Agreement (and each

  
 5 

 
agreement executed and delivered by it in connection herewith) or, to the extent so required, such consent, approval, authorization, order, registration, filing or notice has been obtained, made
or given (as applicable) and is still in full force and effect. Notwithstanding the foregoing, except with respect to Patents that are abandoned or expired as of the Effective Date, Seller has paid and, as of the Effective Date, is current on the
payment of all maintenance fees, annuities, and the like, due and owing to any governmental bodies and other third parties in connection with the Transfer Assets, and Seller has obtained all necessary intellectual property assignments from inventors
to Seller in connection with the Transfer Assets, except, in each case, as would not reasonably be expected to have a material adverse effect. 

(d) Seller has good and marketable title to and, on the Closing Date, Seller will convey to Purchaser, all of the Transfer Assets, free and
clear from any lien, security interest or other encumbrance. 
 (e) The execution, delivery and performance by Seller of this Agreement and
the consummation of the transactions contemplated hereby will not conflict with, or result in a breach of or a constitute a default under, or result in the creation of any lien, security interest or other encumbrance upon the Transfer Assets under,
any provision of (i) Seller’s certificate of incorporation or bylaws; (ii) any applicable law; or (iii) any contract to which Seller is a party or by which any Transfer Asset is bound. 

(f) There is no judicial, governmental or administrative action, investigation, audit, claim, suit, arbitration, proceeding or other litigation
to which Seller or any of its affiliates is a party, or to which the Transfer Assets are subject, that is pending or, to the Knowledge of Seller, threatened. No order, judgment, settlement agreement or stipulation has been issued or entered into
that restricts in any respect the use, provision, transfer, assignment or licensing of the Transfer Assets. 
 (g) Except for the
representations and warranties contained in this Section 8, neither Seller nor any other person or entity makes any other express or implied representation or warranty with respect to Seller, any of its affiliates or the transactions
contemplated by this Agreement, and Seller disclaims any other representations or warranties, whether made by Seller, any of its affiliates, or any of their respective officers, directors, employees, agents or representatives. Except for the
representations and warranties contained in this Section 8, Seller hereby disclaims all liability and responsibility for, or any use by Purchaser or its affiliates or representatives of, any representation, warranty, projection, forecast,
statement or information made, communicated or furnished (orally or in writing) to Purchaser or its affiliates or representatives (including any opinion, information, projection or advice that may heretofore have been or may hereafter be made
available to Purchaser or its affiliates or representatives, whether in any “data rooms,” “management presentations,” or “break out sessions,” in response to questions submitted by or on behalf of Purchaser or otherwise
by any director, officer, employee, agent, or representative of Seller or any of its respective affiliates). The parties agree that any matter, condition or set of facts which is more specifically (rather than generally or by implication) covered in
any of the representations and warranties of this Section 8 shall be solely governed by such more specific representation and warranty without reference to or inclusion within a more generalized representation and warranty that but for this
sentence could be applicable to such matter, condition or set of facts. 

  
 6 

 9. Representations and Warranties of Purchaser. Purchaser represents and warrants to
Seller, as follows: 
 (a) Purchaser (i) is a corporation duly organized, validly existing, and in good standing under the laws of its
jurisdiction of incorporation and (ii) has all requisite corporate power and authority to execute and deliver this Agreement and to perform the transactions contemplated hereby. 

(b) The execution, delivery, and performance by Purchaser of this Agreement and the consummation of the transaction contemplated hereby are
within the power of Purchaser and have been duly authorized by all necessary actions on the part of Purchaser. The execution of this Agreement by Purchaser constitutes, or will at the Closing constitute, a legal, valid and binding obligation of
Purchaser, enforceable against Purchaser in accordance with its terms, except as limited by bankruptcy, insolvency, or other laws of general application relating to or affecting the enforcement of creditors’ right generally and general
principles of equity. 
 (c) No consent, approval, authorization or order of, or registration or filing with, or notice to, any court or
governmental agency or body having jurisdiction or regulatory authority over Purchaser (or any of its properties) is required for (i) Purchaser’s execution and delivery of this Agreement (and each agreement executed and delivered by it in
connection herewith) or (ii) the consummation by Purchaser of the transactions contemplated by this Agreement (and each agreement executed and delivered by it in connection herewith) or, to the extent so required, such consent, approval,
authorization, order, registration, filing or notice has been obtained, made or given (as applicable) and is still in full force and effect. 

(d) No person or entity acting on behalf of Purchaser or any of its affiliates or under the authority of any of them is or will be entitled to
any “brokers” or “finders” fee or any other commission or similar fee, directly or indirectly, from Purchaser or any of its affiliates in connection with any of the transactions contemplated hereby. 

(e) Notwithstanding anything contained in this Agreement to the contrary, Purchaser acknowledges and agrees that Seller is not making any
representations or warranties whatsoever, express or implied, beyond those expressly given by Seller in Section 8, and Purchaser acknowledges and agrees that, except for such representations and warranties contained therein, the Transfer Assets
of Seller are being transferred to Purchaser on a “where is” and, as to condition, “as is” basis. Any claims Purchaser may have for breach of representation or warranty shall be based solely on the representations and warranties
of Seller set forth in Section 8. Purchaser further represents that none of Seller, its affiliates nor any other person or entity has made, and Purchaser has not relied upon, any representation or warranty, express or implied, as to the
accuracy or completeness of any information regarding Seller, the Transfer Assets or the transactions contemplated by this Agreement not expressly set forth in Section 8 and Purchaser hereby expressly disclaims any reliance on any
representations or warranties other than those expressly set forth in Section 8. Purchaser hereby acknowledges and agrees that none of Seller, any of its affiliates nor any other person or entity will have or be subject to any liability to
Purchaser or any other person or entity resulting from the distribution to Purchaser or its representatives or Purchaser’s use of any such information, including any confidential memoranda distributed on behalf of Seller relating to the
Transfer Assets or other publications, data room information or any 

  
 7 

 
other document or information in any form provided to Purchaser or its representatives in connection with the sale of the Transfer Assets and the transactions contemplated hereby other than this
Agreement including its exhibits and the documents delivered by Seller at the Closing pursuant to express requirements of this Agreement. Purchaser acknowledges that it (i) has conducted, to its satisfaction, its own independent investigation
of the condition of the Transfer Assets and the business of Seller in making its determination to proceed with the transactions contemplated by this Agreement, Purchaser has relied on the results of its own independent investigation and, except with
respect to those representations or warranties expressly set forth in Section 8, waives any right it may have against Seller with respect to any omission of any kind on the part of Seller of any potentially material information other than a
failure to disclose information constituting material exceptions to the representations and warranties of set forth in Section 8, (ii) had adequate access to Seller’s books and records, contracts, agreements and documents, and
employees, agents and representatives; and (iii) has had such opportunity to seek accounting, legal and other advice or information in connection with its entry into this Agreement and the other documents referred to herein relating to the
consummation of the transactions contemplated hereby and thereby as it has seen fit. 
 10. Survival; Limitations of Liability. All
representations and warranties contained in this Agreement shall survive the Closing and shall terminate on the earlier of (i) date that is forty-five (45) days following the Closing Date or (ii) the closing date of the Merger. IN NO
EVENT WILL SELLER BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR RELATED TO THIS AGREEMENT (INCLUDING LOSS OF PROFITS, USE, DATA, OR OTHER ECONOMIC ADVANTAGE), HOWSOEVER ARISING,
EITHER OUT OF BREACH OF THIS AGREEMENT (INCLUDING BREACH OF EXPRESS OR IMPLIED WARRANTY), NEGLIGENCE, STRICT LIABILITY, TORT OR ANY OTHER THEORY, EVEN IF THE OTHER PARTY HAS BEEN PREVIOUSLY ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT FOR ANY
CLAIMS BASED UPON OR ARISING FROM (A) ANY ACTION SEEKING EQUITABLE REMEDY OR SPECIFIC PERFORMANCE BROUGHT AGAINST SELLER FOR FAILURE TO DELIVER THE TRANSFER ASSETS AS CONTEMPLATED BY SECTION 1, OR (B) SELLER’S ACTUAL FRAUD (AS
DEFINED BELOW), SELLER’S LIABILITY FOR DAMAGES ARISING UNDER THIS AGREEMENT SHALL BE LIMITED TO THE VALUE OF THE PURCHASE AMOUNT. Recovery of the Purchase Amount by Purchaser shall be Seller’s sole liability and Purchaser’s sole
remedy for the matters described in this Section 10, and Purchaser shall not be entitled to any other remedy or indemnification rights or claims of any nature whatsoever against Seller, its affiliates or any other person or entity in respect
thereof or otherwise in connection with this Agreement. For purposes of this Agreement, “Actual Fraud” means an inaccurate representation or warranty contained in this Agreement if, at the time such representation or warranty was
made, Seller had actual knowledge of the inaccuracy of such representation or warranty and failed to notify Purchaser in writing of, or otherwise correct, the same. 

11. Expenses. Purchaser and Seller shall each bear their own expenses incurred in connection with the transactions contemplated by this
Agreement. 

  
 8 

 12. Transfer Taxes. Purchaser shall pay all sales, use, excise, stamp, documentary,
filing, recording, transfer or similar fees or taxes or governmental charges, as levied by any taxing authority or governmental agency in connection with the sale and transfer of Transfer Assets contemplated by this Agreement. Prior to the Closing
Date, (a) Purchaser shall deliver to Seller evidence that these transactions are exempt from sales tax, or (b) Purchaser shall remit to Seller any sales tax due as a result of these transactions. Seller hereby agrees to file all necessary
documents with respect to such amounts in a timely manner. 
 13. Notices. Any notice or other communication provided for herein or
given hereunder to a party hereto shall be in writing, and shall be deemed given when personally delivered to a party set forth below or when sent by telecopy providing a transmission confirmation (provided that such notice is immediately sent by a
recognized overnight delivery service), or three (3) days after mailed by first class mail, registered, or certified, return receipt requested, postage prepaid, or when delivered by a nationally-recognized overnight delivery service, with proof
of delivery, delivery charges prepaid, in any case addressed as follows. 
 To Seller: 

Aerpio Pharmaceuticals, Inc. 
 c/o
Regina Marek 
 10663 Loveland-Madeira Road #168 

Loveland, Ohio 45140 
 with a copy
to: 
 Goodwin Procter LLP 
 100
Northern Avenue 
 Boston, MA 02210 

Attention: Kingsley Taft 
 To
Purchaser: 
 EyePoint Pharmaceuticals, Inc. 

480 Pleasant Street, Suite A210 

Watertown, MA 02472 
 Attention:
Chief Legal Officer 
 14. Miscellaneous. 

(a) Entire Agreement. This Agreement, together with the schedules and exhibits attached hereto, constitutes the entire agreement of the
parties hereto regarding the purchase and sale of the Transfer Assets, and all prior agreements, understandings, representations and statements regarding such subject matter, oral or written, are superseded hereby. 

(b) Captions. Section captions used in this Agreement are for convenience only, and do not affect the construction of this Agreement.

 (c) Counterpart Execution. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original
and all of which shall together constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by facsimile transmission or by e-mail in .PDF or similar
electronic format shall be effective as delivery of a manually executed counterpart thereof and shall be deemed an original signature for all purposes. 

  
 9 

 (d) Severability. If any provision of this Agreement shall for any reason be held to
be invalid or unenforceable, such invalidity or unenforceability shall not affect any other provision of this Agreement, but this Agreement shall be construed as if such invalid or unenforceable provision had never been contained in this Agreement.

 (e) Amendments and Waivers. No amendment of any provision of this Agreement shall be valid unless the same shall be in writing and
signed by Purchaser and Seller, and no waiver of any provision of this Agreement shall be valid unless the same shall be in writing and signed by the party against which such waiver is to be enforced. No waiver by any party hereto of any default,
misrepresentation, condition precedent or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any other default, misrepresentation, condition precedent or breach of warranty or covenant hereunder or
affect in any way any rights arising by virtue of any prior or subsequent such occurrence. 
 (f) Governing Law. This Agreement shall
be governed by and interpreted in accordance with the internal laws of the Commonwealth of Massachusetts (without reference to conflicts of law principles). 

(g) Waiver of Trial by Jury. SELLER AND PURCHASER HEREBY EXPRESSLY WAIVE ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, CAUSE
OF ACTION, OR PROCEEDING ARISING UNDER OR WITH RESPECT TO THIS AGREEMENT, OR IN ANY WAY CONNECTED WITH, OR RELATED TO, OR INCIDENTAL TO, THE DEALINGS OF THE PARTIES HERETO WITH RESPECT TO THIS AGREEMENT OR THE TRANSACTIONS RELATED HERETO OR THERETO,
IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND IRRESPECTIVE OF WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE. SELLER AND PURCHASER HEREBY AGREE THAT ANY SUCH CLAIM, DEMAND, ACTION, CAUSE OF ACTION, OR PROCEEDING SHALL BE DECIDED BY A
COURT TRIAL WITHOUT A JURY AND THAT ANY PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE OTHER PARTY OR PARTIES HERETO TO WAIVER OF ITS OR THEIR RIGHT TO TRIAL BY JURY.

 (h) Submission to Jurisdiction; Selection of Forum. EACH PARTY HERETO (A) AGREES THAT IT SHALL BRING ANY ACTION OR PROCEEDING
IN RESPECT OF ANY CLAIM ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTAINED IN OR CONTEMPLATED BY THIS AGREEMENT, WHETHER IN TORT OR CONTRACT OR AT LAW OR IN EQUITY, EXCLUSIVELY IN (I) THE UNITED STATES DISTRICT COURT FOR
THE DISTRICT OF MASSACHUSETTS OR IN THE EVENT THAT SUCH COURT LACKS SUBJECT MATTER JURISDICTION OVER THE ACTION OR PROCEEDING, (II) IN AN APPROPRIATE STATE COURT LOCATED IN THE COUNTY OF SUFFOLK, MASSACHUSETTS (THE “CHOSEN
COURT”), (B) IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE CHOSEN COURT, (C) WAIVES, TO THE EXTENT PERMITTED BY APPLICABLE LAW, 

  
 10 

 
ANY OBJECTION TO LAYING VENUE IN ANY SUCH ACTION OR PROCEEDING IN THE CHOSEN COURT, (D) WAIVES ANY ARGUMENT THAT THE CHOSEN COURT IS AN INCONVENIENT FORUM OR DOES NOT HAVE JURISDICTION OVER
ANY PARTY THERETO, AND (E) AGREES THAT SERVICE OF PROCESS UPON ANY PARTY IN ANY SUCH ACTION OR PROCEEDING SHALL BE EFFECTIVE IF NOTICE IS GIVEN IN ACCORDANCE WITH SECTION 13 OF THIS AGREEMENT. 

(i) Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an
ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any
of the provisions of this Agreement. Any reference to any federal, state, local, or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. The word
“including” shall mean “including without limitation.” 
 (j) No Third-Party Beneficiaries. This Agreement shall
not confer any rights or remedies upon any person or entity other than the parties hereto and their respective successors and permitted assigns. 

(k) Successor and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties named herein and their
respective successors and permitted assigns. Neither party may assign its rights or obligations hereunder without obtaining the prior written consent of the other party; provided, however, that each party shall be entitled, without the prior written
consent of the other party, to assign its rights and obligations under this Agreement to an affiliate or to its successor in connection with the sale of all or substantially all of its business or assets related to this Agreement, whether by way of
merger, consolidation, sale of stock, sale of assets, operation of law or otherwise, subject in each case to the assignee agreeing in writing to be bound by the terms and conditions of this Agreement. Any attempted assignment, delegation or transfer
by a party in violation hereof shall be null and void. Subject to the foregoing, this Agreement shall be binding on the parties and their successors and permitted assigns. 

(l) Confidentiality. 
 i.
Purchaser agrees that it will treat in complete confidence all documents, materials and other information, made available by Seller to the Purchaser in connection with the transaction contemplated herein or the negotiation of this Agreement (the
“Confidential Information”) and shall use such Confidential Information solely to evaluate the proposed purchase and sale of the Transfer Assets (the “Purpose”); provided, however, that after Closing Date Purchaser
may use or disclose any Confidential Information included in the Transfer Assets or otherwise necessary to exercise its rights or obligations under this Agreement. Purchaser shall not, directly or indirectly, disclose, publish, divulge, furnish or
make accessible to anyone all or any portion of the Confidential Information, other than (A) to Purchaser’s employees and consultants who are required to have access to such Confidential Information in connection with the Purpose,
(B) to Purchaser’s professional advisers (e.g., lawyers and accountants), provided that any and all such employees and consultants are bound by written agreements or, in the case of professional advisers, ethical duties, respecting the
Confidential Information in the manner set forth in this Agreement and (C) retention of a copy of the Materials that constitute electronic 

  
 11 

 
records by Seller for ordinary archival and recordkeeping purposes. If the transactions contemplated hereby are not consummated, the Purchaser will promptly return to the Seller all Confidential
Information. In addition to the restrictions set forth in this Section 14(l), but subject to the terms of Section 14(m), each party agrees that it shall not, at any point prior to or after the
Closing Date, without the prior written consent of the other party, disclose the existence or terms or conditions of this Agreement. 
 ii.
Confidential Information shall not include any information that (A) at the time of disclosure is available to the public, (B) after the date of disclosure becomes generally available to the public, except through a breach of this
Section 14(l), (C) is independently developed by the employees or agents of the Purchaser without use of or reference to the Confidential Information, (D) that is received from a third party without restriction
and without breach of any agreement between such third party and the Seller. 
 iii. In the event that the Purchaser is required by law to
make any disclosure of any of the Confidential Information, by subpoena, judicial or administrative order or otherwise, the Purchaser shall first give written notice of such requirement to the Seller, and shall permit the Seller to intervene in any
relevant proceedings to protect its interests in the Confidential Information, and provide full cooperation and assistance to the Seller in seeking to obtain such protection. 

iv. Each party acknowledges that a breach by it of any of the terms of this Agreement would cause irreparable harm to the other party for
which the other party could not be adequately compensated by money damages. Accordingly, each party agrees that, in addition to all other remedies available to the other party in an action at law, in the event of any breach or threatened breach by a
party of the terms of this Section 14(l), the other party shall, without the necessity of proving actual damages or posting any bond or other security, be entitled to seek temporary and permanent injunctive relief,
including, but not limited to, specific performance of the terms of this Section 14(l). 
 (m) Public
Announcements. No party shall issue or make any public announcement, press release or other public disclosure regarding this Agreement or its subject matter without the prior written approval of the other party, except for any such disclosure
that is, in the opinion of the disclosing party’s counsel, required by applicable law (including securities regulations) or the rules of a stock exchange on which the securities of the disclosing party are listed. Notwithstanding anything to
the contrary contained in this Agreement, following the Closing, (i) Purchaser and its licensees, sublicensees and other collaborators shall be permitted, without the prior approval of or prior notice to Seller, to disclose for any purpose, and
to make publications and public presentations regarding, progress and results with respect to the development and commercialization of the Transfer Assets; and (ii) Purchaser shall be permitted, without the prior approval of or prior notice to
Seller, to disclose the existence and terms of this Agreement, other than the amount of the Purchase Price, to actual and potential investors, licensees, sublicensees, collaborators and acquirers on a reasonable need-to-know basis under circumstances that reasonably ensure the confidentiality thereof. If a party is, in the opinion of its counsel, required by applicable law (including securities regulations) or the
rules of a stock exchange on which its securities are listed to make a public disclosure regarding this Agreement or its subject matter, such party shall, if practicable under the circumstances, submit the proposed

  
 12 

 
disclosure in writing to the other party and provide the other party a reasonable opportunity to comment thereon. The contents of any public announcement, press release or other public disclosure
that has been made in compliance with this Section 14(l) may then be re-released by any party without a requirement for advance notice or re-approval. 

(n) Termination. Each of Seller and Purchaser shall have the right to terminate its obligations to complete the Closing and the
transactions contemplated in connection therewith in the event that the other party materially breaches this Agreement and such breach is not cured within thirty (30) days after such other party receives notice from the first party of such
material breach. For the avoidance of doubt, the Joint Escrow Instructions provide that the Purchaser and Seller shall instruct the Escrow Agent to release the Purchase Amount to Purchaser following any such termination. 

[Signature Page Follows] 

  
 13 

 IN WITNESS WHEREOF, Purchaser and Seller have caused this Agreement to be executed as of the
Effective Date. 
  

			
	AERPIO PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Joseph Gardner

	Name: Joseph Gardner
	Title: President
	
	EYEPOINT PHARMACEUTICALS, INC.
		
	By:	 	 /s/ George Elston

	Name: George Elston
	 Title: Chief Financial Officer and

Head of Corporate Development

 Signature page to Asset Purchase Agreement 

 EXHIBIT A 

BILL OF SALE 
 [Omitted
pursuant to Item 601(a)(5) of Regulation S-K] 
 EXHIBIT B 

TRANSFER ASSETS 
 Patents and Patent
Applications 
 ATTACHMENT A 
  

											
	 Country
	  	Application No.	  	Filing
Date	  	Patent No.	  	Patent
Date	  	 Title

	United States	  	60/816,730	  	06/27/2006	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	60/816,731	  	06/27/2006	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	60/816,825	  	06/27/2006	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	11/823,086	  	06/26/2007	  	7,622,593	  	11/24/2009	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	11/821,846	  	06/26/2007	  	7,795,444	  	09/14/2010	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	11/821,868	  	06/26/2007	  	7,589,212	  	09/15/2009	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	12/624,072	  	11/23/2009	  	8,258,311	  	09/04/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	13/309,452	  	12/01/2011	  	8,338,615	  	12/25/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	13/691,757	  	12/01/2012	  	8,946,232	  	02/03/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	13/936,450	  	07/08/2013	  	8,895,563	  	11/25/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

											
	United States	  	13/309,445	  	12/01/2011	  	8,329,916	  	12/11/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	14/569,106	  	12/12/2014	  	9,126,958	  	09/08/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	14/252,140	  	04/14/2014	  	9,284,285	  	03/15/2016	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	15/016,599	  	02/05/2016	  	9,795,594	  	10/24/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	15/705,639	  	09/15/2017	  	10,463,650	  	11/05/2019	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	16/577,808	  	09/20/2019	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	17/096,548	  	11/12/2020	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	12/558,169	  	09/11/2009	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	12/850,026	  	08/04/2010	  	8,106,078	  	01/31/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	12/467,430	  	05/18/2009	  	8,188,125	  	05/29/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	13/626,590	  	09/25/2012	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	13/626,614	  	09/25/2012	  	8,846,685	  	09/30/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	14/938,526	  	11/11/2015	  	RE46,592	  	10/31/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	WO	  	PCT/
US2007/014822	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 2 

											
	WO	  	PCT/
US2007/014823	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	WO	  	PCT/
US2007/014824	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Europe	  	7809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Europe	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Europe	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Europe	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Europe	  	12196179.1	  	06/27/2007	  	2592073	  	08/30/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Europe	  	17187910.9	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Europe	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Europe	  	14166121.5	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Europe	  	17182516.9	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Germany	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Germany	  	12196174.2	  	06/27/2007	  	602007052457.1	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 3 

											
	Germany	  	602007052232.3	  	06/27/2007	  	2592073	  	08/30/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Germany	  	602007053259.0	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Germany	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Germany	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Germany	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	France	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	France	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	France	  	12196179.1	  	06/27/2007	  	2592073	  	08/30/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	France	  	14166121.5	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	France	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	France	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	France	  	7809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United Kingdom	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 4 

											
	United Kingdom	  	12196179.1	  	06/27/2007	  	2592073	  	08/30/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United Kingdom	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United Kingdom	  	14166121.5	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United Kingdom	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United Kingdom	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United Kingdom	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Austria	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Austria	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Austria	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Austria	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Austria	  	14166121.5	  	06/27/2007	  	2803663	  	11/29/2007	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Austria	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Belgium	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Belgium	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 5 

											
	Belgium	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Belgium	  	07809909.0	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Belgium	  	07809907.4	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Belgium	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Bulgaria	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Bulgaria	  	7809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Bulgaria	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Lithuania	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Lithuania	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Lithuania	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Latvia	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Latvia	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Latvia	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 6 

											
	Switzerland	  	7809909	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Switzerland	  	7809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Switzerland	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Switzerland	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Switzerland	  	14166121.5	  	06/27/2007	  	2803663	  	11/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Switzerland	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Cyprus	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Cyprus	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Cyprus	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Czech Republic	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Czech Republic	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Czech Republic	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Czech Republic	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Denmark	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 7 

											
	Denmark	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Denmark	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Denmark	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Denmark	  	14166121.5	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Denmark	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Estonia	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Estonia	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Estonia	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Spain	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Spain	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Spain	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Spain	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Spain	  	14166121.5	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 8 

											
	Spain	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Finland	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Finland	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Finland	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Finland	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Finland	  	14166121.5	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Finland	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Greece	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Greece	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Greece	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Hungary	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Hungary	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Hungary	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Iceland	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 9 

											
	Iceland	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Iceland	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Ireland	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Ireland	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Ireland	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Ireland	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Ireland	  	12196179.1	  	06/27/2007	  	2592073	  	08/30/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Ireland	  	14166121.5	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Ireland	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Italy	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Italy	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Italy	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Italy	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 10 

											
	Italy	  	12196179.1	  	06/27/2007	  	2592073	  	08/30/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Italy	  	14166121.5	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Italy	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Luxembourg	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Luxembourg	  	7809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Luxembourg	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Malta	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Malta	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Malta	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Monaco	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Monaco	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Monaco	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Netherlands	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Netherlands	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 11 

											
	Netherlands	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Netherlands	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Netherlands	  	14166121.5	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Netherlands	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Poland	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Poland	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Poland	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Poland	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Poland	  	14166121.5	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Poland	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Portugal	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Portugal	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Portugal	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 12 

											
	Portugal	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Portugal	  	14166121.5	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Portugal	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Romania	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Romania	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Romania	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Sweden	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Sweden	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Sweden	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Sweden	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Sweden	  	14166121.5	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Sweden	  	17191765.1	  	06/27/2007	  	3323815	  	10/07/2020	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Slovenia	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Slovenia	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 13 

											
	Slovenia	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Slovakia	  	07809909.0	  	06/27/2007	  	2041129	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Slovakia	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Slovakia	  	07809908.2	  	06/27/2007	  	2038265	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Turkey	  	07809909.0	  	06/27/2007	  	TR 2014
12834 T4	  	09/03/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Turkey	  	07809907.4	  	06/27/2007	  	2041102	  	11/12/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Turkey	  	07809908.2	  	06/27/2007	  	TR 2015
04305 T4	  	03/18/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Turkey	  	12196174.2	  	06/27/2007	  	2592072	  	09/20/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Turkey	  	14166121.5	  	06/27/2007	  	2803663	  	11/29/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Australia	  	2007265453	  	06/27/2007	  	2007265453	  	05/03/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Australia	  	2007265454	  	06/27/2007	  	2007265454	  	02/09/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Australia	  	2007265455	  	06/27/2007	  	2007265455	  	02/23/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Australia	  	2012200253	  	06/27/2007	  	2012200253	  	10/18/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Brazil	  	PI
0713570-0	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 14 

											
	Brazil	  	PI 0713357-0	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Brazil	  	PI 0713349-9	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Canada	  	2,657,096	  	06/27/2007	  	2,657,096	  	01/21/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Canada	  	2,657,107	  	06/27/2007	  	2,657,107	  	01/07/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Canada	  	2,656,915	  	06/27/2007	  	2,656,915	  	08/07/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	China	  	200780030939.0	  	06/27/2007	  	ZL200780030939.0	  	08/08/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	China	  	200780030984.6	  	06/27/2007	  	ZL200780030984.6	  	10/30/2013	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	China	  	200780031040.0	  	06/27/2007	  	ZL200780031040.0	  	05/30/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Colombia	  	9007333	  	06/27/2007	  	3672	  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Colombia	  	9007334	  	06/27/2007	  	3673	  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Colombia	  	9007327	  	06/27/2007	  	2408	  	10/29/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Hong Kong	  	09108319.8	  	06/27/2007	  	1129386	  	01/22/2016	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Hong Kong	  	13112445.1	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 15 

											
	Hong Kong	  	09108320.5	  	06/27/2007	  	1129387B	  	10/02/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Hong Kong	  	13112446	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Hong Kong	  	09108321.4	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Hong Kong	  	15104703.3	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Israel	  	196128	  	06/27/2007	  	196128	  	11/30/2013	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Israel	  	196129	  	06/27/2007	  	196129	  	06/25/2013	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Israel	  	196130	  	06/27/2007	  	196130	  	07/31/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	India	  	515/DELNP/2009	  	06/27/2007	  	280469	  	02/22/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	India	  	513/DELNP/2009	  	06/27/2007	  	289597	  	11/15/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	India	  	512/DELNP/2009	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Indonesia	  	W00200804210	  	06/27/2007	  	IDP000047234	  	08/09/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Indonesia	  	W-00200804213	  	06/27/2007	  	IDP000045140	  	03/14/2017	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Indonesia	  	W-00200804212	  	06/27/2007	  	IDP000040030	  	12/21/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 16 

											
	Japan	  	2009-518226	  	06/27/2007	  	5232778	  	03/29/2013	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Japan	  	2013-062411	  	06/27/2007	  	5860427	  	12/25/2015	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Japan	  	2009-518227	  	06/27/2007	  	5261383	  	05/02/2013	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Japan	  	2013-029649	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Japan	  	2015-178320	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Japan	  	2015-178321	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Japan	  	2017-213854	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Japan	  	2017-213855	  	06/27/2007	  		  		  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Japan	  	2009-518228	  	06/27/2007	  	5201740	  	02/22/2013	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Korea	  	10-2009-7001678	  	06/27/2007	  	1155365	  	06/05/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Korea	  	10-2009-7001694	  	06/27/2007	  	1179087	  	08/28/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Korea	  	2009-7001692	  	06/27/2007	  	1157844	  	06/13/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Mexico	  	MX/a/2009/000288	  	06/27/2007	  	321351	  	06/24/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Mexico	  	MX/a/2009/000289	  	06/27/2007	  	303155	  	09/06/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 17 

											
	Mexico	  	MX/a/
2009/000290	  	06/27/2007	  	279959	  	10/14/2010	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	New Zealand	  	574407	  	06/27/2007	  	574407	  	06/05/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	New Zealand	  	574406	  	06/27/2007	  	574406	  	05/07/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	New Zealand	  	574405	  	06/27/2007	  	574405	  	05/07/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Philippines	  	1-2009-500031	  	06/27/2007	  	1-2009-500031	  	01/30/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Philippines	  	1-2009-500032	  	06/27/2007	  	1-2009-500032	  	05/07/2014	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Philippines	  	1-2009-500033	  	06/27/2007	  	1-2009-500033	  	07/31/2013	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Russian Federation	  	2009102516	  	06/27/2007	  	2447065	  	12/10/2011	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Russian Federation	  	2009102538	  	06/27/2007	  	2435763	  	12/10/2011	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Russian Federation	  	2009102537	  	06/27/2007	  	2430101	  	09/27/2011	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Singapore	  	200809619-0	  	06/27/2007	  	149161	  	01/31/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Singapore	  	200809621-6	  	06/27/2007	  	148804	  	07/29/2011	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	Singapore	  	200809622-4	  	06/27/2007	  	148805	  	07/29/2011	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

  
 18 

											
	South Africa	  	2009/00559	  	06/27/2007	  	2009/00559	  	06/30/2010	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	South Africa	  	2009/00492	  	06/27/2007	  	2009/00492	  	06/30/2010	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	South Africa	  	2009/00558	  	06/27/2007	  	2009/00558	  	04/24/2012	  	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
						
	United States	  	61/144,022	  	01/12/2009	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	United States	  	61/184,986	  	06/08/2009	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	United States	  	14/075,809	  	11/08/2013	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	United States	  	15/443,353	  	02/27/2017	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	United States	  	16/719,317	  	12/18/2019	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	United States	  	15/930,583	  	05/13/2020	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	United States	  	13/968,269	  	08/15/2013	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	United States	  	13/724,396	  	12/21/2012	  	9,096,555	  	08/04/2015	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	United States	  	12/677,512	  	03/22/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	WO	  	PCT/US2010/020817	  	01/12/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Europe	  	10729682.4	  	01/12/2010	  	2385763	  	11/16/2011	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Germany	  	10729682.4	  	01/12/2010	  	2385763	  	11/16/2011	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	France	  	10729682.4	  	01/12/2010	  	2385763	  	11/16/2011	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	United Kingdom	  	10729682.4	  	01/12/2010	  	2385763	  	11/16/2011	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME

  
 19 

											
	Austria	  	10729682.4	  	01/12/2010	  	2385763	  	04/18/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Belgium	  	10729682.4	  	01/12/2010	  	2385763	  	04/18/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Switzerland	  	10729682.4	  	01/12/2010	  	2385763	  	04/18/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Denmark	  	10729682.4	  	01/12/2010	  	2385763	  	04/18/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Spain	  	10729682.4	  	01/12/2010	  	2385763	  	04/18/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Finland	  	10729682.4	  	01/12/2010	  	2385763	  	04/18/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Ireland	  	10729682.4	  	01/12/2010	  	2385763	  	s04/18/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Italy	  	10729682.4	  	01/12/2010	  	2385763	  	04/18/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Netherlands	  	10729682.4	  	01/12/2010	  	2385763	  	04/18/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Norway	  	10729682.4	  	01/12/2010	  	2385763	  	04/18/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Poland	  	10729682.4	  	01/12/2010	  	2385763	  	04/18/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Portugal	  	10729682.4	  	01/12/2010	  	2385763	  	04/18/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Sweden	  	10729682.4	  	01/12/2010	  	2385763	  	04/18/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Turkey	  	10729682.4	  	01/12/2010	  	2385763	  	04/18/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Australia	  	2010203352	  	01/12/2010	  	2010203352	  	11/06/2014	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Australia	  	2014202211	  	01/12/2010	  	2014202211	  	09/15/2016	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Australia	  	2016203254	  	01/12/2010	  	2016203254	  	01/03/2019	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME

  
 20 

											
	Brazil	  	PI 1006898-8	  	01/12/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Canada	  	2,748,814	  	01/12/2010	  	2,748,814	  	02/25/2014	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Canada	  	2,838,846	  	01/12/2010	  	2,838,846	  	01/19/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	China	  	201080011867.7	  	01/12/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	China	  	201810637424.7	  	01/12/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	China	  	201910044287.0	  	01/12/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Hong Kong	  	12104707.2	  	01/12/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Indonesia	  	W00201102787	  	01/12/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Indonesia	  	P00201900995	  	01/12/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Israel	  	214047	  	01/12/2010	  	214047	  	02/01/2017	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Israel	  	248340	  	01/12/2010	  	248340	  	12/21/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Israel	  	261374	  	01/12/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	India	  	4961/DELNP/2011	  	01/12/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Japan	  	2011-545536	  	01/12/2010	  	5558489	  	06/13/2014	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Japan	  	2014-116250	  	01/12/2010	  	5957035	  	06/24/2016	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Korea	  	10-2011-7018768	  	01/12/2010	  	1495950	  	02/16/2015	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Malaysia	  	PI 2011003558	  	01/12/2010	  	MY-158804-A	  	11/15/2016	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME

  
 21 

											
	Mexico	  	MX/a/2011/007419	  	01/12/2010	  	346984	  	04/07/2017	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	New Zealand	  	594535	  	01/12/2010	  	594535	  	01/07/2014	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Philippines	  	1-2011-501369	  	01/12/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Russian Federation	  	2011133833	  	01/12/2010	  	2539917	  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Russian Federation	  	2014146121	  	01/12/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Singapore	  	201104563-0	  	01/12/2010	  	172312	  	04/19/2017	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Singapore	  	10201702247S	  	01/12/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	South Africa	  	2011/05679	  	01/12/2010	  	2011/05679	  	04/25/2012	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Thailand	  	1101001105	  	01/12/2010	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME
						
	Vietnam	  	1-2011-01745	  	01/12/2010	  		  		  	COMPOUNDS THAT INHIBIT THE INTRACELLULAR CATALYTIC SITE OF PROTEIN TYROSINE PHOSPHATASE BETA (PTP-B) MOLECULE AND COMPOSITIONS COMPRISING THE SAME
						
	United States	  	61/223,260	  	07/06/2009	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	United States	  	13/783,311	  	03/03/2013	  	8,883,832	  	11/11/2014	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	United States	  	14/272,689	  	05/08/2014	  	9,174,950	  	11/03/2015	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

  
 22 

											
	United States	  	14/864,462	  	09/24/2015	  	9,949,956	  	04/24/2018	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	United States	  	15/913,392	  	03/06/2018	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	United States	  	16/582,619	  	09/25/2019	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	United States	  	12/677,550	  	12/01/2010	  	8,569,348	  	10/29/2013	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	WO	  	PCT/US2010/020822	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Europe	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Europe	  	19159755.8	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Germany	  	10797461.0	  	01/12/2010	  	60 2010
057 581.0	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	France	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

  
 23 

											
	United Kingdom	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Austria	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Belgium	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Switzerland	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Denmark	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Spain	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Finland	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Ireland	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Italy	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

  
 24 

											
	Netherlands	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Norway	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Poland	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Portugal	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Sweden	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Turkey	  	10797461.0	  	01/12/2010	  	2451279	  	03/13/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Australia	  	2010271105	  	01/12/2010	  	2010271105	  	08/28/2014	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Brazil	  	PI 1006897-0	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Canada	  	2,748,765	  	01/12/2010	  	2,748,765	  	07/22/2014	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

  
 25 

											
	China	  	201080012192.8	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	China	  	201410144271.4	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	China	  	201510713404.X	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Hong Kong	  	12105753.2	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Israel	  	214048	  	01/12/2010	  	214048	  	03/01/2017	  	COMPOSITIONS FOR PREVENTING METASTASIS OF MELANOMA OR LUNG CANCER
						
	Israel	  	248514	  	01/12/2010	  		  		  	COMPOSITIONS FOR PREVENTING METASTASIS OF MELANOMA OR LUNG CANCER
						
	India	  	5406/DELNP/
2011	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Indonesia	  	W00201102788	  	01/12/2010	  	IDP000045935	  	05/18/2017	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Japan	  	2011-554058	  	01/12/2010	  	5536113	  	05/09/2014	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

  
 26 

											
	Japan	  	2014-048238	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Japan	  	2015-183047	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Japan	  	2017-80657	  	01/12/2010	  	6505153	  	04/05/2019	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Japan	  	2019-58234	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Korea	  	2011-7018742	  	01/12/2010	  	10-1426125	  	07/28/2014	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Malaysia	  	PI 2011003556	  	01/12/2010	  	MY-160399-A	  	03/15/2017	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Mexico	  	MX/a/2011/007420	  	01/12/2010	  	328717	  	03/20/2015	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	New Zealand	  	594537	  	01/12/2010	  	594537	  	05/01/2014	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Philippines	  	1-2011-501370	  	01/12/2010	  	1-2011-501370	  	07/21/2017	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Russian Federation	  	2011133835	  	01/12/2010	  	2519123	  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

  
 27 

											
	Singapore	  	201104564-8	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Singapore	  	10201505672T	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	South Africa	  	2011/05678	  	01/12/2010	  	2011/05678	  	04/25/2012	  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Thailand	  	1101001097	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	Vietnam	  	1-2011-01744	  	01/12/2010	  		  		  	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
						
	United States	  	61/390,899	  	10/07/2010	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULAZATION AND RELATED DISEASES
						
	United States	  	13/253,397	  	10/05/2011	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULAZATION AND RELATED DISEASES
						
	United States	  	14/300,385	  	01/10/2014	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
						
	United States	  	15/462,326	  	03/17/2017	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES

  
 28 

											
	United States	  	16/513,103	  	07/16/2019	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
						
	United States	  	17/352,698	  	06/21/2021	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
						
	United States	  	15/796,293	  	10/27/2017	  		  		  	PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES
						
	WO	  	PCT/US2011/054873	  	10/05/2011	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULAZATION AND RELATED DISEASES
						
	Europe	  	11831498.8	  	10/05/2011	  	2624916	  	01/17/2018	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Germany	  	11831498.8	  	10/05/2011	  	2624916	  	01/17/2018	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	France	  	11831498.8	  	10/05/2011	  	2624916	  	01/17/2018	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	United Kingdom	  	11831498.8	  	10/05/2011	  	2624916	  	01/17/2018	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Ireland	  	11831498.8	  	10/05/2011	  	2624916	  	01/17/2018	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES

  
 29 

											
	Australia	  	2011312203	  	10/05/2011	  	2011312203	  	11/10/2016	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
						
	Australia	  	2016204410	  	10/05/2011	  	2016204410	  	01/17/2019	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
						
	Brazil	  	BR112013008452-9	  	10/05/2011	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Canada	  	2,818,215	  	10/05/2011	  	2,818,215	  	07/21/2015	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Canada	  	2,890,554	  	10/05/2011	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	China	  	201180059165.0	  	10/05/2011	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	China	  	201610996050.9	  	10/05/2011	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Hong Kong	  	14101185.7	  	10/05/2011	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Israel	  	229786	  	10/05/2011	  	229786	  	05/29/2017	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES

  
 30 

											
	Japan	  	2013-532904	  	10/05/2011	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Japan	  	2015-182301	  	10/05/2011	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Japan	  	2015-182302	  	10/05/2011	  	6243882	  	11/17/2017	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Japan	  	2017-217317	  	10/05/2011	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Korea	  	10-2013-
7011704	  	10/05/2011	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Korea	  	10-2015-
7002121	  	10/05/2011	  	1823924	  	01/25/2018	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
						
	Malaysia	  	PI
2013000970	  	10/05/2011	  	MY-176514-A	  	08/12/2020	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Mexico	  	MX/a/
2013/003890	  	10/05/2011	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Mexico	  	MX/a/
2017/006194	  	10/05/2011	  	361520	  	12/06/2018	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES

  
 31 

											
	New Zealand	  	610230	  	10/05/2011	  	610230	  	11/03/2015	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	New Zealand	  	705624	  	10/05/2011	  	705624	  	01/05/2017	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Philippines	  	1-2013-500577	  	10/05/2011	  	1-2013-500577	  	06/14/2019	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Russian Federation	  	2013120064	  	10/05/2011	  	2600794	  	10/04/2016	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Singapore	  	2013023809	  	10/05/2011	  	189177	  	11/16/2015	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULAZATION AND RELATED DISEASES
						
	South Africa	  	2013/03005	  	10/05/2011	  	2013/03005	  	01/29/2014	  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULAZATION AND RELATED DISEASES
						
	Thailand	  	1301001776	  	10/05/2011	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA AND NEOVASCULAZATION AND RELATED DISEASES
						
	United States	  	61/792,679	  	03/15/2013	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	61/792,868	  	03/15/2013	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	61/882,048	  	09/25/2013	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES

  
 32 

											
	United States	  	61/882,056	  	09/25/2013	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	61/934,570	  	01/31/2014	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	13/999,670	  	03/14/2014	  	9,440,963	  	09/13/2016	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	14/214,413	  	03/14/2014	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	15/098,955	  	04/14/2016	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	15/099,161	  	04/14/2016	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	15/355,910	  	11/18/2016	  	10,220,048	  	03/05/2019	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	15/443,622	  	02/27/2017	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	15/958,346	  	04/20/2018	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	15/958,355	  	04/20/2018	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	15/958,358	  	04/20/2018	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

  
 33 

											
	United States	  	15/969,109	  	05/02/2018	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	16/257,287	  	01/25/2019	  		  		  	COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	16/559,006	  	09/03/2019	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	16/888,247	  	05/29/2020	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United States	  	17/155,463	  	01/22/2021	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	WO	  	PCT/US2014/029723	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Europe	  	14762974.5	  	03/14/2014	  	2967066	  	10/23/2019	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Europe	  	19174479.6	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Germany	  	14762974.5	  	03/14/2014	  	602014055602.7	  	10/23/2019	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	France	  	14762974.5	  	03/14/2014	  	2967066	  	10/23/2019	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United Kingdom	  	1411935.8	  	03/14/2014	  	GB2516561	  	03/09/2016	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

  
 34 

											
	United Kingdom	  	1520656.8	  	03/14/2014	  	2540638	  	01/17/2018	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United Kingdom	  	1709419.4	  	03/14/2014	  	2549865	  	01/17/2018	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	United Kingdom	  	14762974.5	  	14-Mar-2014	  	2967066	  	10/23/2019	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Spain	  	14762974.5	  	14-Mar-2014	  	2967066	  	10/23/2019	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Ireland	  	14762974.5	  	03/14/2014	  	2967066	  	10/23/2019	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Italy	  	14762974.5	  	03/14/2014	  	2967066	  	10/23/2019	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Australia	  	2014233363	  	03/14/2014	  	2014233363	  	10/12/2017	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Australia	  	2017235953	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Brazil	  	1120150237533	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Canada	  	2,903,871	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	China	  	201480028572.9	  	03/14/2014	  	105307498	  	04/16/2019	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

  
 35 

											
	China	  	201910221542.4	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Israel	  	240786	  	03/14/2014	  	240786	  	11/01/2019	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	India	  	9436/DELNP/2015	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Indonesia	  	P00201506598	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Israel	  	267997	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Japan	  	2016-503207	  	03/14/2014	  	6,572,201	  	08/16/2019	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Japan	  	2019-147238	  	03/14/2014	  	6865254	  	04/07/2021	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Japan	  	2021-64106	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Korea	  	10-2015-7029411	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Malaysia	  	PI 2015002288	  	03/14/2014	  	MY-171945-A	  	11/08/2019	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

  
 36 

											
	Malaysia	  	PI2019000040	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Mexico	  	MX/a/2015/011131	  	03/14/2014	  	371382	  	01/28/2020	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Mexico	  	MX/a/2020/001060	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	New Zealand	  	712694	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	New Zealand	  	750667	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Philippines	  	1-2015-502153	  	03/14/2014	  	1-2015-502153	  	11/12/2019	  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Philippines	  	1-2019-502018	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Singapore	  	11201507131W	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	South Africa	  	2015/07387	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	South Africa	  	2020/00522	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
						
	Thailand	  	1501005287	  	03/14/2014	  		  		  	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

  
 37 

											
	United States	  	61/953,680	  	03/14/2014	  		  		  	HPTP-BETA INHIBITORS
						
	United States	  	14/657,276	  	03/14/2014	  	9,994,560	  	06/12/2018	  	HPTP-BETA INHIBITORS
						
	United States	  	15/972,863	  	05/07/2018	  	10,858,354	  	12/08/2020	  	HPTP-BETA INHIBITORS
						
	United States	  	17/062,098	  	10/02/2020	  		  		  	HPTP-BETA INHIBITORS
						
	WO	  	PCT/US2015/020425	  	03/13/2015	  		  		  	HPTP-BETA INHIBITORS
						
	Europe	  	15760687.2	  	03/13/2015	  		  		  	HPTP-BETA INHIBITORS
						
	China	  	201580026210.0	  	03/13/2015	  		  		  	HPTP-BETA INHIBITORS
						
	Japan	  	2016-556997	  	3/13/2015	  	6483148	  	02/22/2019	  	HPTP-BETA INHIBITORS
						
	Japan	  	2018-246712	  	3/13/2015	  	6661744	  	02/14/2020	  	HPTP-BETA INHIBITORS
						
	Japan	  	2019-77696	  	04/16/2019	  		  		  	HPTP-BETA INHIBITORS
						
	United States	  	62/034,695	  	08/07/2014	  		  		  	COMBINATION OF IMMUNOTHERAPIES WITH ACTIVATORS OF TIE-2
						
	United States	  	14/819,871	  	08/06/2015	  	9,539,245	  	01/10/2017	  	COMBINATION OF IMMUNOTHERAPIES WITH ACTIVATORS OF TIE-2
						
	United States	  	15/365,186	  	11/30/2016	  		  		  	COMBINATION OF IMMUNOTHERAPIES WITH ACTIVATORS OF TIE-2
						
	WO	  	PCT/US2015/044030	  	08/06/2015	  		  		  	COMBINATION OF IMMUNOTHERAPIES WITH ACTIVATORS OF TIE-2
						
	United States	  	62/019,002	  	06/30/2014	  		  		  	METHODS OF TREATING SEXUAL DISORDERS WITH ACTIVATORS OF TIE-2

  
 38 

											
	United States	  	62/190,871	  	07/10/2015	  		  		  	METHODS OF TREATING SEXUAL DISORDERS WITH ACTIVATORS OF TIE-2
						
	United States	  	62/361,703	  	07/13/2016	  		  		  	METHODS OF TREATING SEXUAL DISORDERS WITH ACTIVATORS OF TIE-2
						
	United States	  	62/222,481	  	09/23/2015	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	United States	  	15/273,068	  	09/22/2016	  	10,952,992	  	03/23/2021	  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	United States	  	17/150,430	  	01/15/2021	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	WO	  	PCT/US2016/053107	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	Europe	  	16849594.3	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	Australia	  	2016326510	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	Brazil	  	1120180054992	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	Canada	  	2,998,673	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	China	  	201680068508.2	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	India	  	201817014284	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	Indonesia	  	P00201802937	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	Israel	  	258150	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2

  
 39 

											
	Japan	  	2018-534502	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	Korea, Republic of	  	10-2018-7010228	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	Malaysia	  	PI2018000423	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	Mexico	  	MX/a/2018/003542	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	New Zealand	  	740730	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	Philippines	  	1-2018-500658	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	Singapore	  	11201802402U	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	Singapore	  	10201912000W	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	South Africa	  	2018/01795	  	09/22/2016	  		  		  	METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2
						
	United States	  	62/635,102	  	02/26/2018	  		  		  	METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
						
	United States	  	62/790,646	  	01/10/2019	  		  		  	METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
						
	United States	  	16/284,349	  	02/25/2019	  		  		  	METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
						
	United States	  	17/130,687	  	12/22/2020	  		  		  	METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS

  
 40 

											
	WO	  	PCT/US2019/019366	  	02/25/2019	  		  		  	METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
						
	Europe	  	19756688.8	  	02/25/2019	  		  		  	METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
						
	Japan	  	2020-567452	  	02/25/2019	  		  		  	METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
						
	United States	  	62/835,626	  	04/18/2019	  		  		  	METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2
						
	United States	  	62/840,655	  	04/30/2019	  		  		  	METHODS OF TREATING PULMONARY HYPERTENSION USING TIE-2 ACTIVATORS
						
	United States	  	16/850,613	  	04/16/2020	  		  		  	METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2
						
	WO	  	PCT/US2020/028577	  	04/16/2020	  		  		  	METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2
						
	United States	  	62/865,653	  	06/24/2019	  		  		  	FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
						
	United States	  	63/009,083	  	04/13/2020	  		  		  	FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
						
	United States	  	16/908,996	  	06/23/2020	  		  		  	FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
						
	United Kingdom	  	2009592.3	  	06/23/2020	  		  		  	FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
						
	United States	  	62/927,233	  	10/29/2019	  		  		  	SMALL MOLECULE ACTIVATORS OF TIE-2
						
	United States	  	17/082,612	  	10/28/2020	  		  		  	SMALL MOLECULE ACTIVATORS OF TIE-2
						
	WO	  	PCT/US2020/057641	  	10/28/2020	  		  		  	SMALL MOLECULE ACTIVATORS OF TIE-2
						
	United States	  	62/840,068	  	04/29/2019	  		  		  	TIE-2 ACTIVATORS TARGETING SCHLEMM’S CANAL

  
 41 

											
	United States	  	16/860,347	  	04/28/2020	  		  		  	TIE-2 ACTIVATORS TARGETING SCHLEMM’S CANAL
						
	WO	  	PCT/US2020/030224	  	04/28/2020	  		  		  	TIE-2 ACTIVATORS TARGETING THE SCHLEMM’S CANAL
						
	United States	  	62/958,348	  	01/08/2020	  		  		  	COMBINATIONS OF TIE-2 ACTIVATORS AND PROSTAGLANDINS AND USES THEREOF
						
	United States	  	63/089,144	  	10/08/2020	  		  		  	COMBINATIONS OF TIE-2 ACTIVATORS AND PROSTAGLANDINS AND USES THEREOF
						
	United States	  	17/143,394	  	01/07/2021	  		  		  	COMBINATIONS OF TIE-2 ACTIVATORS AND PROSTAGLANDINS AND USES THEREOF
						
	WO	  	PCT/US2021/012407	  	01/07/2021	  		  		  	COMBINATIONS OF TIE-2 ACTIVATORS AND PROSTAGLANDINS AND USES THEREOF
						
	United States	  	63/127,412	  	12/18/2020	  		  		  	DOSAGE FORMS OF TIE-2 ACTIVATORS
						
	United States	  	63/127,411	  	12/18/2020	  		  		  	METHODS FOR MANUFACTURE OF SMALL ACTIVATORS OF TIE-2
						
	United States	  	63/028,317	  	05/21/2020	  		  		  	METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME WITH ACTIVATORS OF TIE-2
						
	WO	  	PCT/US2021/033495	  	05/20/2021	  		  		  	METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME WITH ACTIVATORS OF TIE-2

 Group 2 
  

											
	 Country
	  	Application No.	  	Filing
Date	  	Patent No.	  	Patent
Date	  	 Title

	United States	  	60/790,506	  	04/07/2006	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
						
	United States	  	60/798,896	  	05/09/2006	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)

  
 42 

											
	United States	  	11/784,094	  	04/05/2007	  	7,973,142	  	07/05/2011	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
						
	United States	  	15/430,100	  	02/10/2017	  	9,926,367	  	03/27/2018	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	United States	  	15/894,442	  	02/12/2018	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	United States	  	16/696,212	  	11/26/2019	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	United States	  	16/784,970	  	02/07/2020	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF
						
	United States	  	13/115,180	  	05/25/2011	  	8,524,235	  	09/03/2013	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
						
	United States	  	13/958,990	  	08/05/2013	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
						
	WO	  	PCT/
IB2007/051239	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
						
	Europe	  	07735408.2	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

  
 43 

											
	Europe	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Europe	  	17169315.3	  	04/05/2017	  	3252079	  	07/29/2020	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	United Arab Emirates	  	978/2008	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Austria	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Australia	  	2007237096	  	04/05/2007	  	2007237096	  	12/20/2012	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Belgium	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Brazil	  	PI 0710645-9	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Canada	  	2,648,284	  	04/05/2007	  	2,648,284	  	08/16/2016	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Switzerland	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

  
 44 

											
	China	  	200780011778.0	  	04/05/2007	  	ZL 200780011778.0	  	08/31/2016	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	China	  	201610648805.6	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Colombia	  	08-105786	  	04/05/2007	  	4311	  	08/24/2012	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Germany	  	602007051642.0	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Germany	  	602007060503.2	  	04/05/2017	  	3252079	  	07/29/2020	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Denmark	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Egypt	  	1612/2008	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Spain	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Spain	  	17169315.3	  	04/05/2017	  	3252079	  	07/29/2020	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

  
 45 

											
	Finland	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	France	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	France	  	17169315.3	  	04/05/2017	  	3252079	  	07/29/2020	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	United Kingdom	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	United Kingdom	  	17169315.3	  	04/05/2017	  	3252079	  	07/29/2020	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Indonesia	  	W00200803006	  	04/05/2007	  	IDP000051812	  	07/10/2018	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Ireland	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Israel	  	194550	  	04/05/2007	  	194550	  	10/01/2015	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Israel	  	239320	  	04/05/2007	  	239320	  	05/01/2019	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

  
 46 

											
	Israel	  	263755	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	India	  	8043/DELNP/2008	  	04/05/2007	  	271047	  	01/29/2016	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Italy	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Italy	  	17169315.3	  	04/05/2017	  	3252079	  	07/29/2020	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Japan	  	2009-503719	  	04/05/2007	  	5166398	  	12/28/2012	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Japan	  	2012-223157	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Japan	  	2015-107275	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Japan	  	2016-226664	  	04/05/2007	  	6395791	  	09/07/2018	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Japan	  	2017-131042	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

  
 47 

											
						
	Japan	  	2018-246735	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Korea	  	10-2008-7026944	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Korea	  	10-2011-7024995	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Korea	  	10-2013-7022106	  	04/05/2007	  	1482483	  	01/07/2015	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Morocco	  	PV/31325	  	04/05/2007	  	30353	  	04/01/2009	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Mexico	  	MX/a/2008/012991	  	04/05/2007	  	295062	  	01/23/2012	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Malaysia	  	PI 20080003870	  	04/05/2007	  	MY-150400-A	  	01/15/2014	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Netherlands	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	New Zealand	  	571300	  	04/05/2007	  	571300	  	04/02/2012	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

  
 48 

											
	Philippines	  	1-2008-502246	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Poland	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Portugal	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Russia	  	2008138399	  	04/05/2007	  	2473565	  	01/27/2013	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Russia	  	2011141686	  	04/05/2007	  	2494108	  	09/27/2013	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Sweden	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Singapore	  	200806979-1	  	04/05/2007	  		  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Singapore	  	201102498-1	  	04/05/2007	  	170842	  	04/09/2015	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	San Marino	  	P-200800060	  	04/05/2007	  	SM-AP-200800060	  		  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF

  
 49 

											
	Turkey	  	11155518.1	  	04/05/2007	  	2371865	  	07/12/2017	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	Vietnam	  	1-2008-02466	  	04/05/2007	  	14457	  	08/17/2015	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	South Africa	  	2008/07978	  	04/05/2007	  	2008/07978	  	08/26/2009	  	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
						
	United States	  	61/546,708	  	10/13/2011	  		  		  	TREATMENT OF OCULAR DISEASE
						
	United States	  	13/652,154	  	10/15/2012	  	8,999,325	  	04/07/2015	  	TREATMENT OF OCULAR DISEASE
						
	United States	  	14/627,463	  	02/20/2015	  		  		  	TREATMENT OF OCULAR DISEASES
						
	United States	  	15/463,340	  	03/20/2017	  	10,329,357	  	06/25/2019	  	TREATMENT OF OCULAR DISEASES
						
	United States	  	16/395,972	  	04/26/2019	  		  		  	TREATMENT OF OCULAR DISEASES
						
	United States	  	16/751,824	  	01/24/2020	  		  		  	TREATMENT OF OCULAR DISEASES
						
	WO	  	PCT/US2012/060263	  	10/15/2012	  		  		  	TREATMENT OF OCULAR DISEASE
						
	Europe	  	12840725.1	  	10/15/2012	  	2766044	  	12/11/2019	  	TREATMENT OF OCULAR DISEASE
						
	Europe	  	18202143.6	  	10/15/2012	  		  		  	TREATMENT OF OCULAR DISEASE
						
	Australia	  	2012323849	  	10/15/2012	  	2012323849	  	08/03/2017	  	TREATMENT OF OCULAR DISEASE
						
	Brazil	  	112014008759-8	  	10/15/2012	  		  		  	TREATMENT OF OCULAR DISEASE
						
	Canada	  	2,850,824	  	10/15/2012	  		  		  	TREATMENT OF OCULAR DISEASE

  
 50 

											
	China	  	201280054482.8	  	10/15/2012	  		  		  	TREATMENT OF OCULAR DISEASE
						
	China	  	201710084072.2	  	10/15/2012	  		  		  	TREATMENT OF OCULAR DISEASE
						
	Germany	  	12840725.1	  	10/15/2012	  	602012066453.3	  	12/11/2019	  	TREATMENT OF OCULAR DISEASE
						
	Spain	  	12840725.1	  	10/15/2012	  	2766044	  	12/11/2019	  	TREATMENT OF OCULAR DISEASE
						
	France	  	12840725.1	  	10/15/2012	  	2766044	  	12/11/2019	  	TREATMENT OF OCULAR DISEASE
						
	United Kingdom	  	12840725.1	  	10/15/2012	  	2766044	  	12/11/2019	  	TREATMENT OF OCULAR DISEASE
						
	Hong Kong	  	15101784.1	  	10/15/2012	  		  		  	TREATMENT OF OCULAR DISEASE
						
	Hong Kong	  	15101828.9	  	10/15/2012	  		  		  	TREATMENT OF OCULAR DISEASE
						
	Ireland	  	12840725.1	  	10/15/2012	  	2766044	  	12/11/2019	  	TREATMENT OF OCULAR DISEASE
						
	Italy	  	12840725.1	  	10/15/2012	  	2766044	  	12/11/2019	  	TREATMENT OF OCULAR DISEASE
						
	Japan	  	2014-535978	  	10/15/2012	  		  		  	TREATMENT OF OCULAR DISEASE
						
	Japan	  	2016-178592	  	10/15/2012	  	6259503	  	12/15/2017	  	TREATMENT OF OCULAR DISEASE
						
	Japan	  	2016-178593	  	10/15/2012	  		  		  	TREATMENT OF OCULAR DISEASE
						
	Japan	  	2018-103592	  	10/15/2012	  		  		  	TREATMENT OF OCULAR DISEASE
						
	Japan	  	2018-103593	  	10/15/2012	  		  		  	TREATMENT OF OCULAR DISEASE
						
	Mexico	  	MX/a/2014/004449	  	10/15/2012	  	347226	  	04/19/2017	  	TREATMENT OF OCULAR DISEASE
						
	New Zealand	  	623275	  	10/15/2012	  	623275	  	08/30/2016	  	TREATMENT OF OCULAR DISEASE

  
 51 

											
	United States	  	61/546,697	  	10/13/2011	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	United States	  	61/546,748	  	10/13/2011	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	United States	  	13/652,203	  	10/15/2012	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	United States	  	15/438,218	  	02/21/2017	  	10,150,811	  	12/11/2018	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	United States	  	16/168,060	  	10/23/2018	  	10,815,300	  	10/27/2020	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	United States	  	17/027,034	  	09/21/2020	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	WO	  	PCT/US2012/060273	  	10/15/2012	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	Europe	  	12840220.3	  	10/15/2012	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	Europe	  	18201774.9	  	10/15/2012	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	Australia	  	2012323856	  	10/15/2012	  	2012323856	  	09/07/2017	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	Brazil	  	112014008819-5	  	10/15/2012	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	Canada	  	2,850,830	  	10/15/2012	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	China	  	201280052307.5	  	10/15/2012	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER

  
 52 

											
	China	  	201910768287.5	  	10/15/2012	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	Hong Kong	  	15101641.4	  	10/15/2012	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	Japan	  	2014-535979	  	10/15/2012	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	Japan	  	2017-130652	  	10/15/2012	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	Japan	  	2017-143622	  	07/25/2017	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	Japan	  	2019-87483	  	10/15/2012	  	6706367	  	05/19/2020	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	Japan	  	2019-115666	  	10/15/2012	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	Mexico	  	MX/a/2014/004448	  	10/15/2012	  	363351	  	03/20/2019	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	Mexico	  	MX/a/2019/002983	  	10/15/2012	  		  		  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	New Zealand	  	623283	  	10/15/2012	  	623283	  	08/30/2016	  	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
						
	United States	  	62/054,752	  	24-Sep-2014	  		  		  	VE-PTP EXTRACELLULAR DOMAIN ANTIBODIES DELIVERED BY A GENE THERAPY
						
	United States	  	14/862,948	  	09/23/2015	  		  		  	VE-PTP EXTRACELLULAR DOMAIN ANTIBODIES DELIVERED BY A GENE THERAPY
						
	United States	  	15/815,097	  	11/16/2017	  		  		  	VE-PTP EXTRACELLULAR DOMAIN ANTIBODIES DELIVERED BY A GENE THERAPY
						
	WO	  	PCT/US2015/051719	  	09/23/2015	  		  		  	VE-PTP EXTRACELLULAR DOMAIN ANTIBODIES DELIVERED BY A GENE THERAPY

  
 53 

											
	United States	  	62/364,381	  	07/20/2016	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	United States	  	62/377,072	  	08/19/2016	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	United States	  	15/654,289	  	07/19/2017	  	10,253,094	  	04/09/2019	  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP (HPTP-Beta)
						
	United States	  	16/180,850	  	11/05/2018	  	10,604,569	  	03/31/2020	  	HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
						
	United States	  	16/180,854	  	11/05/2018	  	10,597,452	  	03/24/2020	  	HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
						
	United States	  	16/775,860	  	01/29/2020	  		  		  	HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
						
	United States	  	16/851,420	  	04/17/2020	  		  		  	HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
						
	Europe	  	17831790.5	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	WO	  	PCT/US2017/042855	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	Australia	  	2017299581	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	Brazil	  	1120190012060	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	Canada	  	3,030,298	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP

  
 54 

											
	China	  	201780057896.9	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	Indonesia	  	PID201900449	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	Israel	  	263936	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	India	  	201817049429	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	Japan	  	2019-502696	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	Japan	  	2020-120521	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP (HPTP-ß)
						
	Korea	  	10-2019-7002479	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	Mexico	  	MX/a/2019/000727	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	Malaysia	  	PI2019000120	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	New Zealand	  	749494	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	Philippines	  	1-2019-500145	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	Singapore	  	11201900464T	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	Singapore	  	10201912556V	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP

  
 55 

											
	South Africa	  	2019/00368	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS VE-PTP
						
	South Africa	  	2020/01991	  	07/19/2017	  		  		  	HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)

 Group 3 
  

											
	 Country
	  	Application No.	  	Filing
Date	  	Patent
No.	  	Patent
Date	  	 Title

	United States	  	62/735,331	  	09/24/2018	  		  		  	BISPECIFIC ANTIBODIES THAT TARGET VE-PTP (HPTP-B) AND VEGF
						
	United States	  	62/832,461	  	04/11/2019	  		  		  	MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
						
	United States	  	16/579,078	  	09/23/2019	  	10,894,824	  	01/19/2021	  	MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
						
	United States	  	17/117,993	  	12/10/2020	  		  		  	MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
						
	WO	  	PCT/US2019/052405	  	09/23/2019	  		  		  	MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
						
	Europe	  	19867311.3	  	09/23/2019	  		  		  	MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
						
	China	  	201980077336.9	  	09/23/2019	  		  		  	MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-B (VE-PTP) AND VEGF
						
	Japan	  	2021-516373	  	09/23/2019	  		  		  	MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-ß (VE-PTP) AND VEGF

  
 56 

 EXHIBIT C 

MATERIALS 
 [Omitted
pursuant to Item 601(a)(5) of Regulation S-K] 

  
 57 

 EXHIBIT D 

PATENT ASSIGNMENT 

[Omitted pursuant to Item 601(a)(5) of Regulation S-K] 

  
 58 

 EXHIBIT E 

JOINT ESCROW INSTRUCTIONS 

[Omitted pursuant to Item 601(a)(5) of Regulation S-K] 

  
 59 

 EXHIBIT F-1 

IND TRANSFER LETTER (#1) 

[Omitted pursuant to Item 601(a)(5) of Regulation S-K] 

  
 60 

 EXHIBIT F-2 

IND TRANSFER LETTER (#2) 

[Omitted pursuant to Item 601(a)(5) of Regulation S-K] 

  
 61

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]